(Q40658835)

22 September 2017

title

Interleukin-4 in the treatment of AIDS-related Kaposi's sarcoma (English)

1 reference

22 September 2017

D Templeton

7

0 references

author name string

A Tulpule

1

1 reference

22 September 2017

B Joshi

2

1 reference

22 September 2017

N DeGuzman

3

1 reference

22 September 2017

B M Espina

4

1 reference

22 September 2017

R Mocharnuk

5

1 reference

22 September 2017

O Prakash

6

1 reference

22 September 2017

A M Levine

8

1 reference

22 September 2017

P S Gill

9

1 reference

22 September 2017

publication date

1 January 1997

1 reference

22 September 2017

1 reference

22 September 2017

volume

8

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

79-83

1 reference

Interferon therapy for Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Factors affecting B-cell growth and differentiation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

T-cell and mast cell lines respond to B-cell stimulatory factor 1.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Murine interleukin-4 displays potent anti-tumor activity in vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections – a phase I dose toxicity trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer--a phase I toxicity study and pharmacokinetic analysis.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Interleukin-4 and cancer therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Recombinant interleukin 4 stimulates human immunodeficiency virus production by infected monocytes and macrophages

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Interleukin-4 downregulates interleukin-6 production in human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205424763

7 January 2021

Identifiers

DOI

10.1023/A:1008205424763

1 reference

22 September 2017

1 reference